JOINN Biologics

What JOINN Biologics does

JOINN Biologics is a China-based contract development and manufacturing organization (CDMO) specializing in biologics drug development and manufacturing services. Founded in 2018, the company supports pharmaceutical and biotechnology clients across the full lifecycle of biologic therapeutics, from early-stage development and process development through clinical and commercial manufacturing. The firm operates R&D and manufacturing facilities in Beijing and Chongqing, and has publicly disclosed plans to establish a US facility as part of its international expansion strategy.

The company's business model is service-based, generating revenue through contract R&D and manufacturing engagements on a project-by-project basis, with pricing not publicly disclosed. JOINN sells directly to enterprise pharmaceutical and biotech clients through an account-based sales motion targeting R&D, manufacturing, and procurement leadership. Its go-to-market emphasizes biologics manufacturing as a high-growth, technically complex segment where outsourcing helps clients avoid the capital expenditure of in-house facilities. The firm is pursuing FDA 21 CFR Part 820 certification to access regulated international markets.

JOINN Biologics is venture capital-backed, having raised approximately $210 million cumulatively across disclosed rounds, including a $60 million Series A led by Huagai Capital in December 2019 and a $150 million Series B led by CPE in August 2021, with participation from multiple Chinese institutional investors. The company employs 101-250 people and is led by co-founders Shusheng Geng and Tao He. The Series B capital is earmarked for facility expansion, capacity increases, and regulatory certification efforts.

Name

JOINN Biologics

Legal name

JOINN Biologics

Website

https://joinnbio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

JOINN Biologics is a China-based contract development and manufacturing organization (CDMO) providing end-to-end biologics drug development and manufacturing services to pharmaceutical and biotechnology clients, operating facilities in Beijing and Chongqing with planned US expansion.

Ownership category

akta.pro rank

Product category

Biologics Contract Manufacturing (CDMO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Biologics contract manufacturing
• CDMO services
• Biopharmaceutical development
• Process development
• Clinical manufacturing

Headquarters

HQ city

Richmond

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: JOINN Biologics generates revenue by providing contract R&D and manufacturing services to pharmaceutical and biotech companies. As a CDMO, it likely earns fees for drug substance development, process development, clinical manufacturing, and commercial manufacturing services on a contractual basis. Revenue is primarily service-based, project fee-driven, and likely includes both fixed and variable components tied to project scope and volume.

Go-to-market motion1 record

Distribution channels1 record

Core offering

JOINN Biologics is a contract development and manufacturing organization (CDMO) that provides end-to-end services for biologic drugs, spanning R&D, process development, clinical manufacturing, and commercial manufacturing. The company operates manufacturing and R&D facilities in Beijing and Chongqing, China, with planned expansion into the United States, and is pursuing FDA certification to serve global pharmaceutical and biotechnology clients.

Product overview

JOINN Biologics is a China-based Contract Development and Manufacturing Organization (CDMO) providing biologics development and manufacturing services. The company offers end-to-end CDMO services including R&D and manufacturing of biologic drugs. No specific named products, modules, or branded service offerings are detailed in the available source data.

Differentiator

Problem solved

Functional benefit

Products and services

• Biologics Contract Development and Manufacturing Services

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• WuXi Biologics: WuXi Biologics is the leading China-based biologics CDMO offering end-to-end development and manufacturing services from discovery through commercial supply. It is the most directly comparable peer to JOINN Biologics in geography, service scope, and customer base.
• AGC Biologics: AGC Biologics is a mid-sized global CDMO offering mammalian and microbial biologics contract development and manufacturing. Its scale, service scope, and customer profile closely mirror JOINN Biologics' positioning.
• Pharmaron Biologics: Pharmaron Biologics is a China-rooted global CDMO providing integrated biologics development and manufacturing services. It is a relevant peer given its overlapping geographic footprint and end-to-end biologics CDMO offering.
• GenScript ProBio: GenScript ProBio is the biologics CDMO arm of GenScript, offering gene to GMP biologics services. Its Asia-based, end-to-end biologics service model is comparable to JOINN Biologics.

Broad incumbents

• Samsung Biologics: Samsung Biologics is one of the world's largest biologics CDMOs with massive commercial-scale mammalian cell culture capacity and established FDA-inspected facilities. It represents the global scale benchmark JOINN Biologics is positioning against.
• Lonza: Lonza's Biologics division is a leading global CDMO offering mammalian and microbial biologics development and manufacturing services. It is a comparable incumbent across the same end-to-end service portfolio JOINN Biologics targets.
• Catalent: Catalent provides biologics development, fill-finish, and commercial manufacturing services globally. Its broad service portfolio and established customer base make it a directly relevant incumbent peer.
• Boehringer Ingelheim BioXcellence: BioXcellence is Boehringer Ingelheim's biologics CDMO business offering process development and commercial manufacturing for biopharmaceuticals. It competes for the same commercial-stage contract manufacturing work JOINN Biologics targets.
• MilliporeSigma (BioReliance): MilliporeSigma's BioReliance offering provides biologics contract testing, process development, and manufacturing services. It is a relevant incumbent peer given its role as both a supplier and CDMO to biopharma clients.

Regional players

• STA Pharmaceutical (WuXi STA): STA Pharmaceutical is the small-molecule CDMO arm of WuXi AppTec, though within the same WuXi ecosystem it provides useful reference points on China-based CDMO economics and customer access models relevant to JOINN Biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/joinn-biologics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JOINN Biologics